Cargando…

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

BACKGROUND: Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Harrison K., Lehrer, Jonathan, Alshalalfa, Mohammed, Erho, Nicholas, Davicioni, Elai, Lotan, Tamara L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683385/ https://www.ncbi.nlm.nih.gov/pubmed/29132337 http://dx.doi.org/10.1186/s12885-017-3729-z

Ejemplares similares

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma
por: Alshalalfa, Mohammed, et al.
Publicado: (2019)

Evolving transcriptomic fingerprint based on genome‐wide data as prognostic tools in prostate cancer
por: Alshalalfa, Mohammed, et al.
Publicado: (2015)

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
por: Ramnarine, Varune Rohan, et al.
Publicado: (2018)

Development of a predictive model for stromal content in prostate cancer samples to improve signature performance
por: Boufaied, Nadia, et al.
Publicado: (2019)

Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer
por: Erho, Nicholas, et al.
Publicado: (2012)

Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies
por: Stoyanova, Radka, et al.
Publicado: (2016)

Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1
por: Spans, Lien, et al.
Publicado: (2016)

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
por: Alshalalfa, Mohammed, et al.
Publicado: (2017)

Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
por: Vergara, Ismael A., et al.
Publicado: (2012)

Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer
por: Mitra, Anirban P., et al.
Publicado: (2014)

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
por: Liu, Deli, et al.
Publicado: (2018)

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer
por: Berglund, Anders E., et al.
Publicado: (2018)

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
por: Yang, Lingjian, et al.
Publicado: (2018)

Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases
por: Ding, Yuan C., et al.
Publicado: (2021)

The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
por: Prensner, John R., et al.
Publicado: (2014)

Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer
por: Feng, Ye, et al.
Publicado: (2019)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
por: Singh, Neha, et al.
Publicado: (2021)

Imaging of Neuroendocrine Prostatic Carcinoma
por: Taher, Ahmed, et al.
Publicado: (2021)

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
por: Labbé, David P., et al.
Publicado: (2019)

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
por: Ostano, Paola, et al.
Publicado: (2020)

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies
por: Jäger, Wolfgang, et al.
Publicado: (2015)

Lipid degradation promotes prostate cancer cell survival
por: Itkonen, Harri M, et al.
Publicado: (2017)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

MicroRNA Response Elements-Mediated miRNA-miRNA Interactions in Prostate Cancer
por: Alshalalfa, Mohammed
Publicado: (2012)

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
por: Erho, Nicholas, et al.
Publicado: (2013)

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
por: Kim, Hyun, et al.
Publicado: (2016)

Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus
por: Basatac, Cem, et al.
Publicado: (2020)

Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia
por: Lotan, Tamara L., et al.
Publicado: (2012)

Primary neuroendocrine prostate cancer with adrenal gland metastasis
por: Muñoz López, Antonio Yaromin, et al.
Publicado: (2021)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

FOXA2 is a Sensitive and Specific marker for Small Cell Neuroendocrine Carcinoma of the Prostate
por: Park, Jung Wook, et al.
Publicado: (2017)

Prostatic Metastasis of Pulmonary Large Cell Neuroendocrine Carcinoma
por: Shimizu, Kumi, et al.
Publicado: (2012)

Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes
por: Weiner, Adam B., et al.
Publicado: (2021)

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance
por: Nouri, Mannan, et al.
Publicado: (2017)

The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
por: Chakravarty, Dimple, et al.
Publicado: (2014)

Coordinate MicroRNA-Mediated Regulation of Protein Complexes in Prostate Cancer
por: Alshalalfa, Mohammed, et al.
Publicado: (2013)

Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
por: Handke, Analena, et al.
Publicado: (2023)

Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery
por: Badani, Ketan K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v6pktsujsoaml7dn1vjjganj3q